Luminal-A Breast Cancer: What Causes It? Know Treatment Options

Luminal-A breast cancer carries a more favourable prognosis compared to other subtypes. Its responsiveness to hormone therapies contributes to a higher likelihood of successful treatment outcomes.

Luminal-A breast cancer is a distinctive subtype of breast cancer, and is often misunderstood. It is characterised by the expression of hormone receptors – oestrogen and progesterone – coupled with a lack of HER2 protein overexpression.  ( Image Source :Getty )

By Dr Akshita Singh

Luminal-A breast cancer is a distinctive subtype of breast cancer, and is often misunderstood. It is characterised by the expression of hormone receptors – oestrogen and progesterone – coupled with a lack of HER2 protein overexpression. 

This intricate molecular profile sets Luminal-A apart, influencing both prognosis and treatment strategies.

Prognostic Prowess: A Favourable Outlook

Contrary to misconceptions, Luminal-A breast cancer carries a more favourable prognosis compared to other subtypes. Its responsiveness to hormone therapies and often slower growth rate contribute to a higher likelihood of successful treatment outcomes.

Hormone Receptor Positivity: The Core Identifier

At the heart of Luminal-A lies hormone receptor positivity, specifically oestrogen and progesterone. This characteristic makes endocrine therapies, such as selective oestrogen receptor modulators (SERMs) and aromatase inhibitors, pivotal in managing this subtype.

The landscape of breast cancer treatment has witnessed a paradigm shift with the advent of targeted therapies. For Luminal-A, CDK4/6 inhibitors have emerged as a beacon of hope, disrupting the cell cycle and enhancing the efficacy of hormone therapies.

In the era of precision medicine, understanding the unique molecular signature of Luminal-A allows for a personalised therapeutic approach. This involves a careful balance between surgery, radiation, and systemic therapies tailored to the individual patient's needs.

Luminal-A breast cancer, often overshadowed in discussions about breast cancer subtypes, deserves recognition for its distinct characteristics and promising prognosis. By delving into the molecular intricacies, embracing targeted therapies, and adopting a personalised treatment approach, we pave the way for innovative strides in managing Luminal-A breast cancer.

(The author is a consultant of breast cancer surgery at Narayana Health City in Bangalore).

[Disclaimer: The opinions, beliefs, and views expressed by the various authors and forum participants on this website are personal and do not reflect the opinions, beliefs, and views of ABP News Network Pvt Ltd.]